Latest News

Preformed Line Products (PLPC) just gave income focused investors something new to consider, approving a 5% hike to its quarterly dividend, the first increase since the company listed in 2001. See our latest analysis for Preformed Line Products. The move lands after a strong run, with the latest share price at $231.5 and an impressive year to date share price return of about 80%. The five year total shareholder return of roughly 267% shows that long term momentum has been firmly building. If...

Equinor and partner Aker BP recently announced a major gas and condensate discovery in the Lofn and Langemann wells in Norway’s Sleipner area, estimated at 30 to 110 million barrels of oil equivalent and located close to existing infrastructure for potential low-emission development. Together with Equinor’s ongoing Isflak expansion in the Barents Sea and its first hybrid solar-wind complex in Brazil, these finds highlight how the company is simultaneously expanding upstream reserves and...

NextNav Inc. recently began operating its 5G Positioning, Navigation and Timing (PNT) Network in Santa Clara County, California, using multiple fixed base stations, a standalone 5G core, and its 3D PNT architecture to provide a terrestrial complement and backup to GPS. This deployment uniquely tests a standards-compliant 5G Positioning Reference Signal under real-world conditions, an important step toward offering resilient 3D location and timing services for critical infrastructure, public...

Newell Brands (NWL) just paired a sweeping productivity overhaul, including more than 900 job cuts and 20 Yankee Candle store closures, with lowered Q4 guidance as Latin America sales improve more slowly than management expected. See our latest analysis for Newell Brands. Despite the sweeping restructuring moves, the share price has shown a 1 month share price return of about 18% and a 7 day share price return near 5%. However, that bounce sits against a much steeper year to date share price...

Navan (NAVN) has been under pressure lately, with the stock sliding about 19% over the past month and roughly 30% year to date. This has raised fresh questions about how investors should value its AI-driven travel platform. See our latest analysis for Navan. Zooming out, that sharp recent slide in Navan’s share price sits on top of an already weak year to date share price return. This suggests momentum has clearly cooled as investors reassess both growth runway and execution risk. If Navan’s...

BioMarin Pharmaceutical (BMRN) has quietly slid about 20% this year, even as revenue and net income keep growing. That disconnect is exactly what has value focused biotech investors taking a closer look. See our latest analysis for BioMarin Pharmaceutical. At around $52.99 per share, BioMarin’s roughly 20% year to date share price decline and steep three and five year total shareholder return drawdown suggest sentiment has cooled. At the same time, steady revenue and profit growth hint that...

Pipefy, a process management and AI platform, has expanded the availability of its AI Agents to enterprises across the United States, utilizing Oracle Cloud Infrastructure (OCI) for enhanced performance and scalability. This development allows U.S. companies to automate complex business processes with increased intelligence and security, reflecting a significant commitment to advancing AI capabilities within enterprise solutions. Previously available only in Latin America, Pipefy's AI agents...

As we approach the end of 2025, Canadian markets have shown robust performance, with the TSX climbing by 27% year-to-date amid a backdrop of central bank decisions and labor market surprises. In this environment, growth companies with significant insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business, making them worth considering for investors seeking alignment between management and shareholder interests.

As we approach the end of 2025, Canadian markets are experiencing robust growth, with the TSX delivering impressive double-digit gains. With central bank decisions and labor market dynamics in focus, investors are keenly observing how these factors might influence market trends as we head into 2026. Amidst this backdrop, penny stocks—often associated with smaller or newer companies—remain an intriguing investment area for those seeking growth potential paired with financial strength.

ACEA S.p.A. ( BIT:ACE ), is not the largest company out there, but it saw a double-digit share price rise of over 10...

The board of Genomma Lab Internacional, S.A.B. de C.V. ( BMV:LABB ) has announced that it will pay a dividend of...

Despite an already strong run, Arteris, Inc. ( NASDAQ:AIP ) shares have been powering on, with a gain of 27% in the...

Gold Royalty (NYSEAM:GROY) just closed a $90 million follow on equity offering at around $4 a share, a sizable capital raise that immediately reshapes the balance sheet and future deal making capacity. See our latest analysis for Gold Royalty. That capital raise caps a hectic stretch that also included underwriter changes and a special call about acquiring a cash flowing gold and copper royalty in Brazil. The stock’s 230.65% year to date share price return alongside a 222.83% one year total...

Wondering if Western Union at around $9.61 is a bargain or a value trap? This article will walk you through what the numbers are really saying about the stock. Despite a tough longer term run, with the share price still down 40.8% over 5 years, the stock has bounced recently, gaining 7.6% over the last week and 7.9% over the past month, even though it remains 8.0% lower year to date and 2.5% down over the last year. Part of this shift in sentiment reflects ongoing strategic moves to...

Danaher (DHR) just picked up a fresh Buy rating from Goldman Sachs, and the timing lines up with improving sentiment in life sciences tools, especially bioprocessing equipment where demand signals are finally turning. See our latest analysis for Danaher. The stock has quietly put together a solid run, with a 90 day share price return of 22.27 percent and a 30 day gain of 7.68 percent. The 5 year total shareholder return of 19.30 percent shows long term compounding even though the 1 year total...

Red Rock Resorts (RRR) has quietly put together a strong run this year, and the stock’s recent move higher is prompting investors to revisit how its Las Vegas focused casino portfolio supports that momentum. See our latest analysis for Red Rock Resorts. That 6.4% one day share price jump to about $61 signals investors are leaning back into Red Rock’s local Las Vegas growth story, with year to date share price returns already strong and longer term total shareholder returns reinforcing that...

Earlier this month, Neuren Pharmaceuticals disclosed that the FDA’s pre-IND meeting for its NNZ-2591 program was pushed back by one month to late January 2026, citing an administrative delay that could modestly affect the development timeline for hypoxic ischemic encephalopathy and other rare neurological indications. This seemingly short postponement is important because NNZ-2591 is Neuren’s second key asset, already granted orphan drug designation in the US and EU, and any shift in its...

Regis Healthcare has sold its Ayr and Home Hill aged care homes in Far North Queensland to Ozcare, crystallising an expected one-off pre-tax gain of about A$25 million in FY26 and reducing its regional bed count by 156. This divestment marks a shift toward a leaner, city-focused portfolio that analysts suggest could support more efficient operations and improved margins. Next, we’ll examine how Regis’ move away from regional beds toward higher-efficiency metropolitan facilities could...

If you have been wondering whether MP Materials is still a smart way to play the rare earths theme after its huge run, this breakdown will help you decide if the current price still offers value or if most of the upside is already priced in. The stock has surged an eye catching 266.1% year to date and 206.2% over the last 12 months, even after a modest pullback of around 3% over the past week and month, which naturally raises questions about how much future upside is left versus downside...

Cigna Group (CI) is drawing fresh attention after rolling out a rebate free pharmacy benefit model that aims to simplify drug pricing, cut upfront costs, and potentially reshape how pharmacy benefit managers operate. See our latest analysis for Cigna Group. Investors seem to be slowly warming to the story, with a 1 day share price return of 3.68 percent helping to offset a 90 day share price return of minus 10.07 percent, while the 5 year total shareholder return of 46.87 percent still points...

Griffon (GFF) has quietly outperformed the broader market over the past week and month, and that steady climb is starting to draw attention from investors looking for durable industrial exposure. See our latest analysis for Griffon. The recent 1 month share price return of 7.88 percent, on top of a robust 3 year total shareholder return of 144.18 percent, suggests momentum is still firmly on Griffon’s side as investors reassess its growth and cash generation story. If Griffon’s run has you...

Wondering if Alnylam Pharmaceuticals at around $412 a share is still a smart buy after its huge run, or if the upside has already been priced in. The stock is down 11.3% over the last week and 8.7% over the past month, but even after that pullback it is still up 76.6% year to date and 68.2% over the last 12 months. Those moves have come as investors refocus on Alnylam's RNAi drug pipeline, major partnerships with big pharma, and the growing commercial traction of its approved therapies. The...

Aegon (ENXTAM:AGN) just ripped up its old playbook, planning to shift its head office and legal base to the US, rebrand as Transamerica, launch a €400 million 2026 buyback, and review its UK arm. See our latest analysis for Aegon. The share price has been choppy around the latest announcements, with a 1 day share price return of 2.20% after a weak recent stretch, but the 5 year total shareholder return of 157.92% still points to strong long term momentum. If these strategic moves have you...

Wondering if Perimeter Solutions is still a smart buy after its big run up, or if the easy money has already been made? This article will unpack whether the current price really matches the underlying value. The stock has climbed 2.6% over the last week and 11.9% over the past month, but the real eye catcher is its 126.8% gain year to date and 123.3% return over the last year, on top of a 229.7% rise over three years. That surge has come as investors refocus on wildfire prevention and...